Latest Factor VII Stories
NES-ZIONA, Israel, Feb. 2, 2011 /PRNewswire/ -- PROLOR Biotech, Inc., (NYSE Amex: PBTH), today reported positive results from a comparative study of its biobetter longer-acting version of the hemophilia drug Factor IX (Factor IX-CTP) in Factor IX-depleted hemophilic mice.
A new editorial article, published in the Canadian Medical Association Journal, suggests physicians should be more careful when prescribing drugs "off-label".
The use of recombinant activated factor 7 (rFVIIa) despite its potential for adverse events displays the serious shortcomings of Canada's current drug surveillance system.
SOUTH SAN FRANCISCO, Calif., Dec. 16, 2010 /PRNewswire/ -- Catalyst Biosciences, Inc., the leading company in the discovery and development of engineered proteases, today announced the receipt of a $4.0 million milestone payment from Pfizer Inc.
LAGUNA NIGUEL, Calif., Nov. 19, 2010 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc.
The use of recombinant activated factor 7 (rFVIIa) â€“ a drug used to treat bleeding in hemophiliacs â€“ in patients without hemophilia is not recommended because of the potential for adverse events.
LAGUNA NIGUEL, Calif., Nov. 5, 2010 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration) today announced the Company was awarded two grants, totaling $488,958, under the Qualifying Therapeutic Discovery Projects Grant Program (QTDP).
LAGUNA NIGUEL, Calif., Nov. 3, 2010 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration) today announced the appointment of Karen A. Dawes to the Company's Board of Directors. Ms.
HOBOKEN, N.J., Nov.
WAYNE, N.J., Oct. 26 /PRNewswire/ -- Bayer HealthCare is introducing a fitness program to help children ages 7-12 and young adults ages 13-16 with hemophilia A live active lives.
- A volcanic mudflow.